Silence Therapeutics to Present at the Jefferies Healthcare Conference...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 23, 2024

3-in-4 Canadian parents find it harder to save for their child's future with prices and living expenses going up • The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance • JA Solar Joins United Nations Global Compact's "Forward Faster" Initiative • The Tokyo Station Hotel Expands Carbon Neutral Stay Program to All Rooms to Help Achieve Sustainable World • Zayed Sustainability Prize's Beyond2020 Initiative Deploys Life-saving Digital Mammograms in Costa Rica • The PenFed Foundation Partners with Onward Ops to Empower Veterans Transitioning from Military Service to Civilian World • Shippeo Spring Platform Release Reveals All-new Parcel Tracking, Advanced Carbon Emissions Monitoring Features, and Enhanced Con • Pentair Reports Strong First Quarter 2024 Results • Henry Schein Medical Announces Winner of Its 2024 Rising Star Award • Empowering Communities and Environment: MINISO's ESG Journey • Clean Energy Announces First Injection of Renewable Natural Gas at Victory Farms Dairy • AUSTRALIAN BATTERY MATERIALS INNOVATOR ANNOUNCES US EXPANSION • Nextracker Launches Industry’s First Low Carbon Solar Tracker Solution • Caleres Reports Progress Toward 2025 ESG Goals • FREYR Battery Announces First Quarter 2024 Earnings Release and Conference Call Schedule • TULU 2024 World Indigenous Tourism Summit Opens in Kaohsiung, Taiwan, Gathering 27 Countries to Focus on "Indigenous Cultures an • Carter’s, Inc. Announces Multi-Year Partnership with Boys & Girls Clubs of America to Advance Early Childhood Educatio • New novel explores love, loss and triumph through the eyes of a first-generation Latina lawyer • Ashlee Davidson joins Operation Homefront's National Board of Directors • X-energy Awarded $148.5 Million Investment Tax Credit for First-of-a-Kind TRISO-X Fuel Fabrication Facility

Silence Therapeutics to Present at the Jefferies Healthcare Conference

LONDON , May 31 /Businesswire/ - Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will present at the Jefferies Healthcare Conference on Wednesday, June 7^th at 4:00 – 4:25 PM EDT.

A live webcast of the presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.